MedTrace Logo

Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT01691313 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2015-12-22

Study results available
· View outcomes & findings →

Summary

Evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo, in a dose modification manner, on the conversion of symptomatic atrial fibrillation (a-fib) or flutter of recent onset to normal sinus rhythm.

Conditions

  • Symptomatic Atrial Fibrillation
  • Atrial Flutter

Interventions

DRUG

Vanoxerine

single oral dose

DRUG

Placebo

single oral dose

Sponsors & Collaborators

  • Laguna Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Howard C Dittrich, MD · ChanRx Corp.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-09-30
Completion
2013-10-31

Countries

  • Israel
  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01691313 on ClinicalTrials.gov